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REPLY
The writing group of the “Scientific Statement on the Evaluation
of Syncope” takes this opportunity to respond to the critique of this
document (1) by Dr. Benditt and colleagues. The goal of this
Scientific Statement, as set forth by the sponsoring organizations,
was to provide a concise, practical approach to the initial evaluation
of the patient with syncope within strict length limitations (2). The
document approaches the evaluation of syncope as a clinician
would when a patient presents to the office or hospital with such an
event. The emphasis of this document is placed on the recognition
of life-threatening clinical syndromes.
The criticisms of Dr. Benditt and colleagues can be grouped
into three categories. First, the definition of syncope was inade-
quate. Second, the stated goal of preventing death is not adequate,
and the goal for the evaluation of syncope should also be to
establish a diagnosis and provide a prognosis. Third, the citations
were incomplete.
The definition of syncope as “a transient loss of consciousness”
fits into the category of a practical working definition. Although
there is no uniform consensus on the ideal definition, the defini-
tion often includes reference to the loss of consciousness due to
global cerebral hypoperfusion. Unfortunately, this definition can
be strictly applied only when the mechanism of syncope is firmly
established. The definition used in this document relates to the
clinical presentation, as commonly used and understood, and does
not require a specific mechanistic diagnosis. Academically, one
might prefer a more detailed or thorough definition. However, one
could also argue that any definition intended to be used universally
should be developed by international consensus among appropriate
medical societies. To date, this has not been achieved.
The specific etiology of syncope is identified in only about
one-half of the patients who undergo an evaluation for syncope.
Furthermore, many patients never have a recurrence after an
episode of syncope, and only occasionally is syncope disabling.
Ultimately, one can have many goals for a document of this type.
We chose the identification of the patient at risk of death as the
primary one.
Dr. Benditt and colleagues correctly state that many references
relevant to syncope were not cited. Owing to space considerations
and the document’s focus on the evaluation of syncope, many
excellent papers could not be referenced. We agree that the
“Guidelines on Management (Diagnosis and Treatment) of Syn-
cope” developed by the European Society of Cardiology are
particularly important documents, and we apologize for omitting
them (3,4).
The “Scientific Statement on the Evaluation of Syncope” was
reviewed and evaluated by 50 outside reviewers. The document
was reviewed and approved by the American Heart Association
(AHA), American College of Cardiology Foundation, Heart
Rhythm Society, and the American Autonomic Society. Criticisms
and comments offered by these reviewers and organizations were
responded to and incorporated into the final document. Although
there are inherent limitations to any such document, the writing
group believes that the “Scientific Statement on the Evaluation of
Syncope” achieves the goals set forth by the AHA for this
document, and it provides a concise and practical approach to the
initial evaluation of syncope.
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Examining the Concept
of Preserved Systolic Function
Sophisticated analyses and the size of the Acute Decompensated
Heart Failure National Registry (ADHERE) database strengthen
the characterization of heart failure with preserved systolic func-
tion (PSF) made by Yancy et al. (1). Unfortunately, PSF includes
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ejection fractions (EFs) of 40% to 49% that are, by definition,
abnormal. Excluding borderline abnormal EFs from systolic heart
failure leads to a more homogeneous population wherein manage-
ment is substantially evidence-based. However, including border-
line abnormal EFs in PSF renders the terminology self-
contradictory, because systolic function is normal in diastolic heart
failure (2). Rather than imposing a definition, if the authors query
the frequency distribution of EFs is there a bimodal curve? Where
are the peaks; what are the distributions? Is there significant
overlap? What percent fall into the 40% to 49% range? Are these
patients similar to patients with systolic dysfunction; with diastolic
heart failure (EFs 50%), such that the concept of normal left
ventricular function needs to be revisited; or best considered in a
gray zone, such that they cannot be placed into either group at this
time?
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Effect of Door-to-Balloon
Time on Patient Mortality
The study by McNamara et al. (1) from the National Registry of
Myocardial Infarction (NRMI) found that door-to-balloon time
(DBT) was strongly associated with mortality in both high- and
low-risk patients and in patients presenting early or late after the
onset of symptoms. These findings differ from our analyses from a
large randomized trial and a single-center registry, both of which
found that DBT impacts mortality primarily in high-risk patients
and in those presenting early after the onset of symptoms (2,3).
Several possible explanations account for these differences.
Prolonged DBT may be confounded with other unmeasured
variables that impact mortality. First, DBT may be a surrogate for
quality of care—hospitals with long DBTs may provide subopti-
mal treatment. Data from single-center registries and randomized
trials would be less likely to have this bias. Second, NRMI data on
time from symptom onset to presentation collected from retro-
spective chart reviews may be unreliable because the time of
symptom onset is often not documented in hospital charts. This is
less of a problem in randomized trials or carefully constructed
prospective registries. Finally, and perhaps most importantly,
prolonged DBTs often reflect the underlying severity of illness,
with “sicker” patients requiring longer time for evaluation, stabi-
lization, or treatment of complications prior to percutaneous
coronary intervention (PCI) (e.g., cardiopulmonary resuscitation,
intubation, defibrillation, or insertion of temporary pacemakers or
intra-aortic balloon pumps). These confounding variables are
rarely accounted for in large registries, including NRMI.
In addition, the findings by McNamara et al. (1) that DBT
affects mortality even in patients presenting late contradict the
widely held paradigm regarding the time-sensitivity of reperfusion
therapy originally demonstrated by Reimer et al. (4) and recently
re-emphasized by Gersh et al. (5).
This issue is more than academic. We believe that an excessive
emphasis on minimizing DBT as the overriding quality-of-care
measure by hospitals, insurers, and regulators (and guidelines com-
mittees) may at times detract from optimal patient care. Rushing to
perform primary PCI before stabilizing unstable patients may lead to
laboratory complications and worse clinical outcomes. Indiscriminant
treatment with fibrinolytic therapy of ST-segment elevation myocar-
dial infarction patients presenting at noninterventional hospitals,
rather than transferring appropriate patients for primary PCI,
deprives these patients of the benefits of higher rates of reperfu-
sion, less reinfarction, less intracranial hemorrhage, and in many
cases lower mortality. A recent meta-analysis of randomized trials
with primary PCI versus fibrinolysis has shown primary PCI
reduced mortality even with treatment delays up to 2 h (6).
Decisions regarding triage of patients for primary angioplasty
should thus be based on an assessment of time and risk, and should
utilize common sense. High-risk patients presenting early after the
onset of symptoms with long delays to primary PCI are probably
best treated with fibrinolytic therapy. Most other patients are best
treated with transfer for primary PCI despite longer treatment
delays.
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